Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)

European Respiratory Journal

Volumn 45, Issue 4, 2015, Pages 969-979

  Buhl, Roland ^a   Maltais, François ^b   Abrahams, Roger ^c   Bjermer, Leif ^d   Derom, Eric ^e   Ferguson, Gary ^f   Fležar, Matjaž ^g   Hébert, Jacques ^h   McGarvey, Lorcan ⁱ   Pizzichini, Emilio ^j   Reid, Jim ^k   Veale, Antony ^l   Grönke, Lars ^m   Hamilton, Alan ⁿ   Korducki, Lawrence ^o   Tetzlaff, Kay ^m,p   Waitere Wijker, Stella ^m   Watz, Henrik ^q   Bateman, Eric ^r  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b LAVAL UNIVERSITY   (Canada)

^c Morgantown Pulmonary Clinical Research   (United States)

^d LUND UNIVERSITY   (Sweden)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f Pulmonary Research Institute of Southeast Michigan   (United States)

^g Univerzitetna Klinika Golnik   (Slovenia)

^h Centre de Recherche Appliquée en Allergie de Québec   (Canada)

ⁱ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^j FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^k UNIVERSITY OF OTAGO   (New Zealand)

^l QUEEN ELIZABETH HOSPITAL   (Australia)

^m BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

ⁿ BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^o BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^p UNIVERSITY OF TÜBINGEN   (Germany)

^q Mitglied im DZL   (Germany)

^r UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

OLODATEROL PLUS TIOTROPIUM BROMIDE; SALBUTAMOL; BENZOXAZINE DERIVATIVE; BRONCHODILATING AGENT; OLODATEROL; TIOTROPIUM BROMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INFESTATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOFT MIST INHALER; ST. GEORGE RESPIRATORY QUESTIONNAIRE; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; INTERNATIONAL COOPERATION; MAXIMUM TOLERATED DOSE; METERED DOSE INHALER; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; BENZOXAZINES; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; MALE; MAXIMUM TOLERATED DOSE; METERED DOSE INHALERS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84926500092     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00136014     Document Type: Article

References (28)

1. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013; 14: 49.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf Date last updated: 2014. Date last accessed: 2 June 2014.
3. Tashkin DP, Celli B, Senn S, et al., for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
4. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med 2010; 104: 1460-1472.
5. Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest 2013; 144: 490-497.
6. Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Respir Care 2011; 56: 477-487.
7. Vogelmeier C, Hederer B, Glaab T, et al., for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103.
8. Wise RA, Anzueto A, Cotton D, et al., for the TIOSPIR Investigators. Tiotropium Respimat Inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491-1501.
9. Troosters T, Celli B, Lystig T, et al., on behalf of the UPLIFT® investigators. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trial. Eur Respir J 2010; 36: 65-73.
10. Decramer M, Celli B, Kesten S, et al., for the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
11. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010; 334: 53-62.
12. Casarosa P, Kollak I, Kiechle T, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther 2011; 337: 600-609.
13. Lange P, Aumann J-L, Derom E, et al. The 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies. Eur Respir J 2013; 42: Suppl. 57, 982s.
14. Feldman G, Bernstein JA, Hamilton A, et al. The 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studies. Chest 2013; 144: 749A.
15. Ferguson G, Feldman G, Hofbauer P, et al. Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies. Eur Respir J 2013; 42: Suppl. 57, 5s.
16. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy of olodaterol QD delivered via Respimat® versus placebo and formoterol BID in patients with COPD: Two 48-week studies. Eur Respir J 2013; 42: Suppl. 57, 146s.
17. Koch A, Paggiaro P, Hamilton A, et al. Symptomatic benefit of olodaterol QD delivered via Respimat® versus placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies. Eur Respir J 2013; 42: Suppl. 57, 145s.
18. Maltais F, Kirsten A-M, Hamilton A, et al. Evaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studies. Chest 2013; 144: 748A.
19. Bouyssou T, Schnapp A, Casarosa P, et al. Addition of the new once-daily LABA BI 1744 to tiotropium results in superior bronchoprotection in pre-clinical models. Am J Respir Crit Care Med 2010; 181: abs 4445.
20. 3 antagonist) and ciclesonide (inhaled steroid) on the ovalbumininduced bronchoconstriction in anaesthetized guinea pigs. Eur Respir J 2011; 38: Suppl. 55, 613s.
21. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients. Eur Respir J 2010; 36: Suppl. 54, 1014s.
22. Aalbers R, Maleki-Yazdi MR, Hamilton A, et al. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD. Eur Respir J 2012; 40: Suppl. 56, 525s-526s.
23. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.who.int/respiratory/copd/GOLD-WR-06.pdf Date last updated: 2006. Date last accessed: 5 March 2014.
24. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-1494.
25. Wedzicha JA, Decramer M, Ficker J, et al. Efficacy and safety of QVA149 versus glycopyrronium and tiotropium in severe to very severe COPD: the SPARK study. Am J Respir Crit Care Med 2013; 187: abs A2429.
26. Celli B, Crater G, Kilbride S, et al. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD. Am J Respir Crit Care Med 2013; 187: abs A2435.
27. Derom E, Westerman J, Groenke L, et al. The 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: abs 6727.
28. Jones PW. Estimation and application of the minimum clinically important difference in COPD. Lancet Respir Med 2014; 2: 167-169.